Michele Dilizia Recce's guest appearances

Michele Dilizia Recce

Empowered Patient Podcast

Mark Allen

David Katz

Rosalind Picard

David Solomon

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

OwlTail

Michele Dilizia, Executive Director of Regulatory Affairs and Microbiology, Recce Pharmaceuticals discusses why Recce is focused on developing a new class of broad spectrum synthetic polymer-antibiotics that can be used repeatedly against a wide range of bacteria without contributing to antibiotic resistance.  Michele also speaks to how Recce® 327, Recce's lead asset, is designed to empower doctors with a near universal treatment that can kill multiple types of bacteria in the blood, even superbugs, that can cause sepsis. @ReccePharma #antibioticresistance #syntheticantibodies #infections #superbugs #sepsis Recce.com.au Download the transcript here.

Michele Dilizia, Executive Director of Regulatory Affairs and Microbiology, Recce Pharmaceuticals discusses why Recce is focused on developing a new class of broad spectrum synthetic polymer-antibiotics that can be used repeatedly against a wide range of bacteria without contributing to antibiotic resistance.  Michele also speaks to how Recce® 327, Recce's lead asset, is designed to empower doctors with a near universal treatment that can kill multiple types of bacteria in the blood, even superbugs, that can cause sepsis. @ReccePharma #antibioticresistance #syntheticantibodies #infections #superbugs #sepsis <a href="http://recce.com.au" rel="noopener nofollow" target="_blank">Recce.com.au</a> <a href="http://empoweredpatientradio.com/new-class-of-synthetic-polymer-antibiotics-overcomes-antibiotic-resistance-with-michele-dilizia-recce-pharmaceuticals-transcript" rel="noopener nofollow" target="_blank">Download the transcript here.</a>

New Class of Synthetic Polymer-Antibiotics Overcomes Antibiotic Resistance with Michele Dilizia Recce Pharmaceuticals